Roivant Sciences Ltd Ordinary Shares ROIV 深 沪
已收盘 12-19 16:00:00 美东时间
22.395
+0.605
+2.78%
华盛通- 最 高23.47
- 今 开21.83
- 成交量 576.05万股
- 最 低 19.96
- 昨 收 21.79
- 总市值 154.97亿
- 52周最高 23.47
- 市盈率 静 --
- 换手率 0.83%
- 52周最低 8.73
- 委 比 -25.81%
- 总股本 6.92亿
- 历史最高 23.47
- 量 比 0.53
- 振 幅 16.11%
- 历史最低 1.10
- 每 手 1
- 风险率 3.59%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Roivant Signals Major Pipeline Momentum With Accelerated Timelines
Roivant (NASDAQ: ROIV) outlined accelerated timelines and expanded commercial ambitions for several late-stage programs.
12-12 02:39
Earnings Scheduled For November 10, 2025
Companies Reporting Before The Bell • CBAK Energy Tech (NASDAQ:CBAT) is likely ...
11-10 19:12
Earnings Preview For Roivant Sciences
Roivant Sciences (NASDAQ:ROIV) will release its quarterly earnings report on Mo...
11-07 22:01
470亿港元合作：晶泰控股与哈佛教授Verdine创AI制药史上合作订单新纪录
2025年8月5日，晶泰控股（02228.HK）宣布与哈佛大学教授Gregory Verdine创立的DoveTree正式签署最终协议，合作总规模达470亿港元...
08-07 11:50
Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis
Roivant and Priovant Therapeutics announce a live investor video conference on June 17 to discuss brepocitinib's potential in addressing unmet medical needs for dermatomyositis patients. Brepocitinib, a TYK2/JAK1 inhibitor, is in Phase 3 trials for dermatomyositis and non-infectious uveitis, and Phase 2 for cutaneous sarcoidosis. The event will provide insights into its development and patient benefits.
06-09 20:05
2025年美股Biotech有望大涨 摩根大通首选福泰制药
华尔街金融巨头摩根大通近日发布研报称，对于2025年美股市场的生物科技公司（即Biotech）股价走势持乐观看涨立场，预计Biotech有望跑赢美股大盘，其中美股Biotech领军者之一的福泰制药（VRTX.US）在摩根大通的2025年最佳Biotech选股名单中位列榜首。在美联储开启降息的大背景下，生物科技类股票可谓是最佳受益于降息周期的股票板块，在降息周期之下资金有望从近年来股价持续暴涨且估值处于历史高位的大型科技巨头们转向一些受益于降息周期且估值自2022年以来长期低迷的生物科技股。 据了解，在摩根大通最新发布的研报中，该机构2025年最看好的生物科技公司除了位列股票名单首选位置...
2024-11-26 15:22
Cantor Fitzgerald Reiterates Overweight on Roivant Sciences
Cantor Fitzgerald analyst Louise Chen reiterates Roivant Sciences (NASDAQ:ROIV) with a Overweight.
2024-09-09 21:03
Roivant Says Immunovant Reported Results From Phase 2a Trial Of Batoclimab In Graves' Disease; Says High Dose Batoclimab Achieved 76% Response Rate In Patients Uncontrolled On Antithyroid Drugs At Week 12
mmunovant also disclosed data from several proprietary market research studies that showed a consistent unmet need among ATD treated patients who are intolerant to, uncontrolled on or relapsed after ATDs. Finally,
2024-09-09 19:06
